Featured Pharma Online Editorial

1. Why Isolators Do Not Automatically Ensure Annex 1 Compliance 5/12/2026

   Isolators are powerful tools, but they do not automatically ensure compliance with EU GMP Annex 1. RABS are frequently dismissed too quickly. The difference is not the technology itself, but how it is applied.

2. Gaining An Edge In GLP-1 Production 5/5/2026

   The shortage-driven production of GLP-1 drugs of the past few years is giving way to a long-term operation model characterized by digital enablement and supply chain resilience.

3. How Generic Pharma Manufacturers Can Rebuild Margins Inside The Four Walls 5/4/2026

   The pricing dynamics for generic drugs turns formerly attractive products into high-volume, low-margin commodities. Lean and Six Sigma in four key areas can unlock efficiencies.

4. Challenges And Solutions In Aseptic Evolution 4/22/2026

   Aseptic processing has undergone a considerable evolution over the past 35 years in new equipment, standards, procedures, training and regulation. Navigating these challenges is essential to minimizing risk.

5. U.S. Pharma Tariffs And MFN Become Law After April 2 Update 4/15/2026

   Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them.

6. Lilly's Toolbox For Fast Track Fill Finish Sites 4/1/2026

   Constructing greenfield fill finish sites is always a complex task, but throw in there the added challenge of delivering the site expediently, and the task becomes increasingly complicated.

7. Organic Impurities: New Draft ICH Q3E Guidance For Leachables And Extractables 3/17/2026

   A new draft guidance document from ICH, issued jointly with the EMA, adopts the position that the assessment of leachables and extractables requires a holistic framework for risk evaluation.

8. 9 Pharma Trends To Watch In 2026 2/27/2026

   What does 2026 ultimately hold for the industry? To explore that question, Lawrence Blatt, CEO of Aligos Therapeutics, sat down with me to share his perspective on the trends shaping the year ahead.

9. U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact 2/18/2026

   Beroe Inc.'s Mathini Ilancheran discusses the 2025 U.S. pharma tariff framework and translates it into actionable procurement and outsourcing responses.

10. FDA Issues Final Guidance For pH Adjuster Waiver Requests For Generic Drugs 12/11/2025

    The FDA has issued a final guidance, Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use.